Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
At a preplanned efficacy interim analysis (n=5,637), abemaciclib, a CDK4/6 inhibitor, plus endocrine therapy (ET) demonstrated superior invasive disease-free survival vs ET alone (hazard ratio, 0.75; 95% CI, 0.60 to 0.93, p=0.01).
Source:
Journal of Clinical Oncology
SPS commentary:
Authors’ of a related commentary state monarchE is clearly a positive trial that suggests a potential new role for CDK4/6 inhibition in the management of patients with early-stage breast cancer who present with a very high risk for recurrence, as defined in monarchE. However, it is too early to understand the long-term impact from the adjuvant use of CDK4/6 inhibitors in this setting.